INS and type 2 diabetes mellitus: The treatment effect of empagliflozin on the primary endpoint, its components and total hospitalizations according to T2DM status did not vary according to the prescription of metformin or insulin, or according to BMI, age, or sex at baseline (online supplementary Figure S3).